As part of the Decentralized Trials and Research Alliance's (DTRA) TGIF-DCT podcast series, mdgroup will join forces with Q2 Solutions to explain how tearing down barriers between the various vendors and service providers involved in such studies is a simple yet effective starting point.
Hosted by DTRA founder Craig Lipset, mdgroup's Director of Decentralized Clinical Solutions, Tom Brazier, will present with Q2 Solutions' Decentralized Trial Solutions Director, John Corcoran, and Manager, Stephanie Larimer.
This event will take place on Dec. 9, 12-1pm, EST. This podcast discussion forms part of a series of Clubhouse events, organized by the DTRA, of which mdgroup is a founding member, aimed at providing all stakeholders with an informal space to share DCT experiences and best practice.
Read more about the event here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.